Clario

Clario, now part of Thermo Fisher Scientific, develops clinical trial endpoint technology and evidence generation solutions for pharmaceutical and biotech sponsors, contract research organizations (CROs), and clinical sites. The company provides digital endpoint solutions, connected devices, and AI-driven tools designed to evaluate drug efficacy, safety, and patient quality of life across all phases of drug development, supporting site-based, hybrid, and decentralized clinical trial models.

With over 50 years of experience, Clario has contributed to more than 30,000 clinical trials across more than 100 countries, with translations available in over 100 languages. The company reports that its technologies have supported more than 700 FDA and EMA new drug approvals, representing approximately 70% of FDA and EMA new drug approvals since 2015. Clario offers 24/7 support for both partners and patients, with training and instructions integrated directly into its devices.

Core Endpoint Technology Areas

• Cardiac Safety: Endpoint technology focused on monitoring and assessing cardiac safety signals during clinical trials.
• eCOA (Electronic Clinical Outcome Assessment): Digital tools for capturing patient-reported, clinician-reported, and observer-reported outcomes.
• Medical Imaging: Clario has conducted over 5,000 imaging studies and brings response criteria expertise to oncology and other therapeutic areas.
• Precision Motion: Technology solutions for measuring and analyzing patient movement and physical function as clinical endpoints.
• Respiratory: Endpoint solutions supporting respiratory drug development programs.

Key Capabilities

• Scientific expertise: Hundreds of clinical trial management experts apply therapeutic area and endpoint science across the company's evidence generation technologies, supported by extensive global regulatory experience.
• Global operational scale: Thousands of customer operations professionals deliver deployment capability across more than 100 countries, with regulatory and operational expertise built from tens of thousands of trials.
• AI and validated software: Clario develops engineered and validated clinical trial management software and AI solutions integrated across its endpoint technology portfolio.
• Decentralized and hybrid trial support: The platform is designed to support decentralized, hybrid, and traditional site-based trials, with the stated aim of expanding patient choice and improving diversity and health equity within clinical trials.
• Integrated platform for sponsors, sites, and CROs: The platform combines endpoint technologies with scientific expertise and global scale, with compliance and retention features built into devices and workflows.

Notable Developments and Certifications

• Clario has received ISO 42001 certification for responsible artificial intelligence, audited by Schellman.
• Research published in Biological Psychiatry demonstrated that a speech-latency vocal biomarker supported by Clario's technology can strengthen drug–placebo separation in schizophrenia trials.
• Thermo Fisher Scientific announced its acquisition of Clario in October 2025, with the stated goal of enabling pharma and biotech customers to accelerate innovation with deeper clinical insights.

Clario serves sponsors, CROs, and clinical sites seeking to generate reliable clinical evidence, offering an endpoint technology platform that spans cardiac safety, imaging, eCOA, motion, and respiratory domains, backed by global regulatory expertise and round-the-clock operational support.